Compare · BNR vs ELV
BNR vs ELV
Side-by-side comparison of Burning Rock Biotech Limited (BNR) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNR and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $84.38B, about 875.4x BNR ($96.4M).
- Over the past year, BNR is up 120.5% and ELV is up 38.1% - BNR leads by 82.4 points.
- ELV has been more active in the news (6 items in the past 4 weeks vs 2 for BNR).
- ELV has more recent analyst coverage (23 ratings vs 2 for BNR).
- Company
- Burning Rock Biotech Limited
- Elevance Health Inc.
- Price
- $10.98-5.39%
- $388.99-1.15%
- Market cap
- $96.4M
- $84.38B
- 1M return
- +57.31%
- -1.49%
- 1Y return
- +120.48%
- +38.07%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 2
- 6
- Recent ratings
- 2
- 23
Burning Rock Biotech Limited
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest BNR
- Director Han Yusheng bought $6,182,172 worth of Ordinary Shares (731,410 units at $8.45), increasing direct ownership by 4% to 18,404,086 units (SEC Form 4)
- Burning Rock Announces Founder’s Purchase of Its ADSs
- Burning Rock Reports First Quarter 2026 Financial Results
- SEC Form 6-K filed by Burning Rock Biotech Limited
- Amendment: SEC Form SCHEDULE 13G/A filed by Burning Rock Biotech Limited
- Burning Rock Publishes 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by Burning Rock Biotech Limited
- SEC Form 4 filed by Han Yusheng
- Burning Rock Announces Founder's Purchase of Its ADSs
- SEC Form 3 filed by new insider Deng Feng
Latest ELV
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
- SEC Form 11-K filed by Elevance Health Inc.